Literature DB >> 25946435

Long-term outcomes after transcatheter aortic valve replacement in high-risk patients with severe aortic stenosis: the U.K. Transcatheter Aortic Valve Implantation Registry.

Alison Duncan1, Peter Ludman2, Winston Banya1, David Cunningham3, Damian Marlee3, Simon Davies1, Michael Mullen4, Jan Kovac5, Thomas Spyt5, Neil Moat6.   

Abstract

OBJECTIVES: The U.K. Transcatheter Aortic Valve Implantation Registry reported 30-day and 1-year mortality rates of 7.1% and 21.4%, respectively, for patients who underwent transcatheter aortic valve replacement (TAVR) in the United Kingdom between 2007 and 2009. The study aim was to report long-term outcomes in this same cohort of patients.
BACKGROUND: There are few data on outcomes beyond 3 years after TAVR in any notable number of patients.
METHODS: Data from all TAVR procedures performed in the United Kingdom between January 2007 and December 2009 were prospectively collected. All-cause mortality status was reported in March 2014. Mortality tracking was achieved in 97.7% patients.
RESULTS: The minimal time from replacement to census was 4.1 years, and the maximal time was 7.0 years. The 3- and 5-year survival rates were 61.2% and 45.5%, respectively. Independent predictors of 3-year mortality were renal dysfunction (hazard ratio [HR]: 1.65), atrial fibrillation (HR: 1.36), logistic European System for Cardiac Operative Risk Evaluation (EuroSCORE) ≥18.5 (HR: 1.33), respiratory dysfunction (HR: 1.28), and ventricular dysfunction (left ventricular ejection fraction <30%) (HR: 1.53). Coronary artery disease (HR: 1.28) and age (HR: 1.03) were additional independent predictors of mortality at 5 years. Stroke within 30 days of TAVR was the only independent procedural predictor of mortality at 3 and 5 years (HR: 2.17 at 3 years). Device type, access route, and paravalvular leak did not independently predict long-term outcome.
CONCLUSIONS: In the large U.K. Transcatheter Aortic Valve Implantation Registry, long-term outcomes after TAVR are favorable with 3- and 5-year survival rates of 61.2% and 45.5%, respectively. Long-term survival after TAVR is largely determined by intrinsic patient factors. Other than stroke, procedural variables, including paravalvular aortic leak, did not appear to be independent predictors of long-term survival.
Copyright © 2015 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  UK-TAVI Registry; long-term outcome; predictors of survival; transcatheter valve replacement

Mesh:

Year:  2015        PMID: 25946435     DOI: 10.1016/j.jcin.2015.01.009

Source DB:  PubMed          Journal:  JACC Cardiovasc Interv        ISSN: 1936-8798            Impact factor:   11.195


  27 in total

Review 1.  Transcatheter Aortic Valve Replacement: Comprehensive Review and Present Status.

Authors:  Sameer Arora; Jacob A Misenheimer; Radhakrishnan Ramaraj
Journal:  Tex Heart Inst J       Date:  2017-02-01

2.  Insights on mid-term TAVR performance: 3-year clinical and echocardiographic results from the CoreValve ADVANCE study.

Authors:  Sabine Bleiziffer; Johan Bosmans; Stephen Brecker; Ulrich Gerckens; Peter Wenaweser; Corrado Tamburino; Axel Linke
Journal:  Clin Res Cardiol       Date:  2017-05-08       Impact factor: 5.460

Review 3.  Assessment, treatment, and prognostic implications of CAD in patients undergoing TAVI.

Authors:  Edward Danson; Peter Hansen; Sayan Sen; Justin Davies; Ian Meredith; Ravinay Bhindi
Journal:  Nat Rev Cardiol       Date:  2016-02-11       Impact factor: 32.419

Review 4.  Long term outcomes of transcatheter aortic valve implantation (TAVI): a systematic review of 5-year survival and beyond.

Authors:  Adam Chakos; Ashley Wilson-Smith; Sameer Arora; Tom C Nguyen; Abhijeet Dhoble; Giuseppe Tarantini; Matthias Thielmann; John P Vavalle; Daniel Wendt; Tristan D Yan; David H Tian
Journal:  Ann Cardiothorac Surg       Date:  2017-09

5.  Sex Differences in the Impact of Aortic Valve Calcium Score on Mortality After Transcatheter Aortic Valve Replacement.

Authors:  Parth P Patel; Abdallah El Sabbagh; Patrick W Johnson; Rayan Suliman; Najiyah Salwa; Andrea Carolina Morales-Lara; Peter Pollak; Mohamad Yamani; Pragnesh Parikh; Sushilkumar K Sonavane; Carolyn Landolfo; Mohamad Adnan Alkhouli; Mackram F Eleid; Mayra Guerrero; F David Fortuin; John Sweeney; Peter A Noseworthy; Rickey E Carter; Demilade Adedinsewo
Journal:  Circ Cardiovasc Imaging       Date:  2022-08-03       Impact factor: 8.589

6.  Association of CKD with Outcomes Among Patients Undergoing Transcatheter Aortic Valve Implantation.

Authors:  Florian Lüders; Klaus Kaier; Gerrit Kaleschke; Katrin Gebauer; Matthias Meyborg; Nasser M Malyar; Eva Freisinger; Helmut Baumgartner; Holger Reinecke; Jochen Reinöhl
Journal:  Clin J Am Soc Nephrol       Date:  2017-03-13       Impact factor: 8.237

7.  Long-term outcomes and prosthesis performance after transcatheter aortic valve replacement: results of self-expandable and balloon-expandable transcatheter heart valves.

Authors:  Giuseppe Tarantini; Paola A M Purita; Augusto D'Onofrio; Chiara Fraccaro; Anna Chiara Frigo; Gianpiero D'Amico; Luca Nai Fovino; Marta Martin; Francesco Cardaioli; Mostafa R A Badawy; Massimo Napodano; Gino Gerosa; Sabino Iliceto
Journal:  Ann Cardiothorac Surg       Date:  2017-09

8.  A Glimpse into the Future: In 2020, Which Patients will Undergo TAVI or SAVR?

Authors:  Crochan J O'Sullivan; Peter Wenaweser
Journal:  Interv Cardiol       Date:  2017-05

9.  Utilization of Advanced Cardiovascular Therapies in the United States and Canada: An Observational Study of New York and Ontario Administrative Data.

Authors:  Peter Cram; Saket Girotra; John Matelski; Maria Koh; Bruce E Landon; Lu Han; Douglas S Lee; Dennis T Ko
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2020-01-20

10.  Midregional Proadrenomedullin Improves Risk Stratification beyond Surgical Risk Scores in Patients Undergoing Transcatheter Aortic Valve Replacement.

Authors:  Adam Csordas; Fabian Nietlispach; Philipp Schuetz; Andreas Huber; Beat Müller; Francesco Maisano; Maurizio Taramasso; Igal Moarof; Slayman Obeid; Barbara E Stähli; Martin Cahenzly; Ronald K Binder; Christoph Liebetrau; Helge Möllmann; Won-Keun Kim; Christian Hamm; Thomas F Lüscher
Journal:  PLoS One       Date:  2015-12-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.